MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
534.49
+1.37
+0.26%
After Hours: 534.49 0 0.00% 19:30 09/11 EDT
OPEN
536.02
PREV CLOSE
533.12
HIGH
546.56
LOW
531.37
VOLUME
187.64K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
393.61
MARKET CAP
12.35B
P/E (TTM)
-41.5289
1D
5D
1M
3M
1Y
5Y
1D
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
The Motley Fool · 2d ago
Weekly Report: what happened at MDGL last week (0831-0904)?
Weekly Report · 5d ago
Ten healthcare stocks leading in year-over-year CapEx growth
Seeking Alpha · 09/02 12:02
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Seeking Alpha · 08/31 18:57
Weekly Report: what happened at MDGL last week (0824-0828)?
Weekly Report · 08/31 10:04
Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Simply Wall St · 08/28 19:28
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
The Motley Fool · 08/25 16:20
Weekly Report: what happened at MDGL last week (0817-0821)?
Weekly Report · 08/24 10:04
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.